Stock Profiler

From: Christa Denton <christa.dentonoc(at)>
Date: Mon, 16 Aug 2004 14:31:14 +0000

                           The Growth Stock Report
          Record Earnings Announcement Coming Monday August 16, 2004
                   Biotech Sizzle with Sales and Earnings!!
                   Genex Pharmaceutical, Inc.(OTCBB: GENX)
                  (Treating Bone Related Injuries in China)

          Revenues from 2/10/03 (Inception) to 12/31/03: $1,221,903
          Net Income from 2/10/03 (Inception) to 12/31/03: $450,985
                     Revenues 3 months 3/31/04; $436,208
                     Net Income 3 months 3/31/04: $66,691

          The Company paid $0 for interest and income tax during the
          period ended March 1,2003 and the years ended Dec.31,2003.
                          (Source: 8K Filed 6/29/04)


Look how these Chinese Stocks have done and what they would've made your
portfolio look like if you knew about them:

(OTCBB:CAAS):Closed September 2, 2003 at $4.00. Closed December 31,
2003: $16.65, Up 316%

(OTCBB:CWTD):Closed January 30, 2004 at $1.50. Closed February 17th at
$7.90, Up 426%

Ordinary Investors Like You are Turbocharging Their Portfolios With
these High Octane Stocks. When Some of Them Start to Move, They Really
Take Off.

The interesting thing about companies that do business in China is that
the market and 0pportunity is much, much bigger than in the USA. And
that can mean sweet, juicy pr0fits for savvy investors who take
advantage of them.

This bad boy (GENX) is out of Stealth Mode and is already top line
revenue producing! Do you see where we're going with this? Biotech
Sizzle with Sales and Earnings!!

                    About Genex Pharmaceutical, Inc.

Genex Pharmaceutical, Inc. is a biomedical technology company with
distinctive proprietary technology for an orthopedic device that treats
bone-related injuries. Headquartered in Tianjin, China, the Company
manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400
hospitals in 22 provinces throughout mainland China. RBX is approved by
the State Food and Drug Administration (SFDA) in China (the Chinese
government agency that regulates drugs and medical devices). RBX offers
a modern alternative to traditional methods of treating orthopedic
injuries. (Source: News Release 7/27/04)

       Recent Press Release: July 27th (NEW PRODUCT BEING TESTED)
                      Tuesday July 27, 5:42 pm ET

   Chinese FDA Approves Clinical Trials of Genex's New Dental Product

NEW YORK--(BUSINESS WIRE)--July 27, 2004--Genex Pharmaceutical, Inc.
(stock symbol: GENX; a Delaware corporation, is a profitable biomedical
technology company with a unique product for treating various
bone-related injuries called Reconstituted Bone Xenograft (RBX), which
is a medical device approved by the SFDA (Chinese State Food and Drug
Administration). RBX is suitable for compound or complex bone fractures,
compression fractures and intractable fractures, bone defects, vertebral
column or joint rehabilitation and for bone absence after tumor removal
such as a bone cyst. The SFDA has approved clinical trials of the
company's new product for dental applications, micro-particle RBX. The
clinical trials will focus on orthodontic and periodontal procedures.
Micro-particle RBX provides a minimally invasive technique that will
improve dental surgery procedures and potentially accelerate recovery
from surgeries.

"Approval for clinical trials of micro-particle RBX is a significant
step in the development and expansion of our product pipeline. We are
extending our success of treating orthopedic surgical patients with RBX
to the vast number of dental patients seeking minimally invasive
technologies in orthodontic treatment," commented Mr. Fuzhi Song,
Chairman and CEO of Genex.

According to a National Dental Survey conducted by the PRC Ministry of
Health, from 1995 to 1998, 570 million Chinese people suffer from
advanced tooth decay, 80% of Chinese people over the age of 7 suffer
from permanent tooth decay, 4% over 60 need gum treatment and 2% of the
nation's over 40 population require dental grafting.

              Good Luck and Succesful Trading. Go GENEX!!

DIS-CLAIMER: Information within this email contains "F0RWARD looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not statements of
historical fact and may be "F0RWARD looking statements."F0RWARD looking
statements are based on expectations, estimates and projections at the
time the statements are made that involve a number of risks and
uncertainties which could cause actual results or events to differ
materially from those presently anticipated. F0RWARD looking statements
in this action may be identified through the use of words such as
"projects", "foresee", "expects", "will," "anticipates," "estimates,"
"believes," "understands" or that by statements indicating certain
actions "may," "could," or "might" occur. As with many micro-cap stocks,
today's company has additional risk factors worth noting. Those factors
include: the company advancing cash to related parties and a shareholder
on an unsecured basis: one vendor, a related party through a majority
stockholder, supplies ninety-seven percent of the company's raw
materials: reliance on two customers for over fifty percent of their
business and numerous related party transactions and the need to raise
capital. The Growth Stock Report does not represent that the
information contained in this message states all material facts or does
not omit a material fact necessary to make the statements therein not
misleading.All information provided within this em-ail pertaining to
investing, stocks, securities must be understood as information provided
and not investment advice. The Growth Stock Report advises all readers
and subscribers to seek advice from a registered professional securities
representative before deciding to trade in stocks featured within this
em-ail. None of the material within this report shall be construed as
any kind of investment advice or solicitation.Many of these companies
are on the verge of bankruptcy. You can lose all your money by
investing in this stock. The publisher of The Growth Stock Report is
not a registered investment ADVIS0R. Subscribers should not view
information herein as legal, tax, accounting or investment advice. Any
reference to past performance(s) of companies are specially selected to
be referenced based on the favorable performance of these companies.
You would need perfect timing to acheive the results in the examples
given. There can be no assurance of that happening. Remember, as
always, past performance is ne-ver indicative of future results and a
thorough due diligence effort, including a review of a company's
filings, should be completed prior to investing.The Growth Stock Report
has no relationship with CAAS and CWTD. (Source for Price
Information:Yahoo Finance Historical). In compliance with the Securities
Act of 1933, Section17(b),The Growth Stock Report discloses the receipt
of twelve thousand dollars from a third party, not an officer, director
or affiliate shareholder for the circulation of this report. Be aware
of an inherent conflict of interest resulting from such compensation due
to the fact that this is a paid adver-tisement. All factual information
in this report was gathered from public sources, including but not
limited to Company Websites, SEC Filings and Company Press Releases.
The Growth Stock Report believes this information to be reliable but can
make no guar-antee as to its accuracy or completeness. Use of the
material within this em-ail constitutes your acceptance of these terms.

To Unsubscribe: send mail to majordomo(at)
with "unsubscribe de-bsd-test" in the body of the message
Received on Mon 16 Aug 2004 - 16:23:13 CEST

search this site